Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 91Neoplasm Metastasis 7Prostatic Neoplasms, Castration-Resistant 5Breast Neoplasms 3Neoplasms 2Castration-resistant Prostate Cancer 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Hyperaldosteronism 1Cushing Syndrome 1Carcinoma, Transitional Cell 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

enzalutamide 4abiraterone 2sapanisertib 1onvansertib 1inavolisib 1abemaciclib 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-Resistant Prostate Cancer × Abiraterone Acetate × Clear all
NCT02125357 2020-08-07

Sequencing Abiraterone and Enzalutamide in mCRPC

British Columbia Cancer Agency

Phase 2 Completed
202 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡